Aladdin Healthcare Technologies SE
- WKN: A12ULL
- ISIN: DE000A12ULL2
- Land: Deutschland
Nachricht vom 08.04.2020 | 08:00
Aladdin Healthcare Technologies SE: Aladdin Healthcare Technologies SE Q1-Performance Review: Breakthrough for faster Drug Development and successful implementation of AI tools against the spread of COVID-19 - Benchmark of Business Plan exceeded
DGAP-News: Aladdin Healthcare Technologies SE
/ Key word(s): Interim Report
Aladdin Healthcare Technologies SE Q1-Performance Review: Breakthrough for faster Drug Development and successful implementation of AI tools against the spread of COVID-19 - Benchmark of Business Plan exceeded
- Minimum Viable Product (MVP) for Alzheimer's Disease Diagnosis Tool completed
- Development and implementation of Knowledge Graphs for COVID-19 and age-related diseases
- Health Risk Assessment Tool (HRA) for real-time risk management of COVID-19 built
- Successful development of a safe Temperature Screening System for mass health surveillance
- Software focused on age-related diseases for Wearables developed
Aladdin Healthcare achieves further milestones in the development of Artificial Intelligence (AI) based health monitoring tools in the first quarter of 2020. The company is already well ahead on its own strategic plan.
Alzheimer's Disease Diagnosis Tool completed
A knowledge graph is a graph-structured knowledge database, where facts are represented in the form of relationships between and from different data providers. In a knowledge graph, entities (nodes) are related to each other by means of the so-called edges and are contextualized thematically. Aladdin's AI team, through the use of advanced text mining techniques, was able to extract biomedical knowledge from over 30 million research articles and to construct a large scale knowledge graph with more than 800 thousand entities and over 10 million edges among diseases, targets, compounds, biomarkers and genes.
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE comments: "Our AI-powered literature review algorithm can process thousands of published literature papers and establish the key relationships between various diseases and risk factors. This culminates in the construction of our unique knowledge graph. We will be able to optimise our models considerably over the next 12 months to significantly increase the reliability and efficiency of diagnoses. Early stage diagnosis is a critical factor in the development of highly effective drugs."
AI-powered Tools against COVID-19 validated
Wade Menpes-Smith, CEO of Aladdin Healthcare Technologies SE adds: "By using the latest Big Data and AI technology, we want to deliver and create a network of answers to the most urgent questions in the fight against the coronavirus pandemic. This includes further information on the transmission, incubation and environmental stability of COVID-19, as well as data about risk factors, genetics, origin and further development. At the same time, we hope to build a larger knowledge base of potential vaccines and therapeutics."
Aladdin is now constantly oriented to significantly contribute to stop the COVID-19 expansion and save millions of lives by implementing its AI tools and its technical expertise.
As already announced at the end of March, Aladdin partnered with a China hardware technology company, to develop a novel system which delivers an AI-powered Body Temperature Screening with the ability to offer mass health surveillance, detecting individual temperatures in crowds without using a temperature gun or manually checking.
Furthermore, Aladdin launched a "Health Risk Assessment Tool (HRA)" as web and mobile application to manage risk assessment of potential COVID-19 suspect cases and patients for global use. The AI application provides users with a real-time risk assessment of individuals infected with coronavirus, combining Artificial Intelligence with augmented reality.
Development of software for wearables for age-related diseases
More information about the Company's milestones for the first quarter 2020, supported and explained by charts and graphics can be found at aladdinid.com/press-releases
About Aladdin Healthcare Technologies SE
For further information
Aladdin Healthcare Technologies Ltd.
|Company:||Aladdin Healthcare Technologies SE|
|Unter den Linden 10|
|Listed:||Regulated Market in Dusseldorf|
|EQS News ID:||1017597|
|End of News||DGAP News Service|
Aladdin Healthcare Technologies SE
Aladdin Healthcare Technologies SE achieves fu ...
Aladdin Healthcare Technologies SE: Release ac ...
Aladdin Healthcare Technologies SE wins EUR 1. ...
Aladdin Healthcare Technologies SE promotes dr ...
EQS Group: Rating lautet Kaufen
Die Vorzeichen für die EQS Group AG sind positiv. Ein wesentlicher Umsatztreiber für das Jahr 2020 sollte die Migration von Bestandskunden vom COCKPIT in das COCKPIT 2.0 bedeuten. Darüber hinaus erwarten wir ein gutes Wachstum in den übrigen Bereichen, da die EQS mit vielen Produkten auch von der Coronakrise profitieren kann. So werden z. B. Online-Hauptversammlungen, Webcasts und Telefonkonferenzen vermehrt gebucht: Unseres Erachtens sollte es auch zu einer höhere Anzahl an Pflichtmeldungen von Unternehmen kommen. Unser Kursziel liegt bei 91,50 €, das Rating lautet weiter Kaufen.
Der AKTIONÄR News
25. Mai 14:50 Nvidia mit neuem Rekordhoch – die Rallye geht weiter
25. Mai 14:45 RWE im Höhenflug – kommt jetzt der Gap-Close?
News im Fokus
Deutsche Lufthansa AG: Wirtschaftsstabilisierungsfonds stimmt dem Lufthansa Stabilisierungspaket zu
25. Mai 2020, 16:39
Original-Research: Netfonds AG (von Montega AG): Kaufen
25. Mai 2020